Dako Receives FDA Approval of a Genetic Test for Patients With Breast Cancer
Posted on: Tuesday, 15 January 2008, 06:00 CST
The US Food and Drug Administration has given Dako PMA approval to market its TOP2A FISH pharmDx(TM) assay. The assay is intended as an adjunct in determining the prognosis for high-risk breast-cancer patients.
Dako, a world-leading provider of cancer-diagnostic solutions, is the first company to receive FDA approval for a TOP2A diagnostic test for breast-cancer patients.
The test, TOP2A FISH pharmDx(TM), is marketed to assess clinical breast-cancer tissue specimens for changes in the status of the TOP2A. This information aids physicians in evaluating the prognosis for breast-cancer patients, since patients with normal TOP2A status have a better outcome than patients with TOP2A gene amplifications or deletions. TOP2A FISH pharmDx(TM) provides new prognostic information for additional groups of patients and may serve as an adjunct to existing HER2-testing.
"We are very pleased to announce the FDA approval of our TOP2A FISH pharmDx(TM) test. The TOP2A FISH pharmDx(TM) kit adds a new dimension to the way breast cancer will be treated in the future, giving oncologists and pathologists a reliable tool when assessing the disease prognosis for individual patients," says Patrik Dahlen, CEO and President of Dako.
TOP2A FISH pharmDx(TM) is part of Dako's range of pharmacodiagnostic products, and is based on the fluorescence in-situ hybridization (FISH) technique. TOP2A FISH pharmDx(TM) also has the EC-label within the European Union.
About TOP2A
TOP2A is a molecular target for the pharmacological action of anthracyclines. Anthracycline-based chemotherapy with doxorubicin or epirubicin is one of the most active regimens in breast-cancer treatment. However, these compounds have serious acute and long-term side effects, such as cardiotoxicity and leukemia. The predictive implications of TOP2A amplifications for optimal use of anthracycline therapy have been established for many European patients. It is an area of active research with promising initial results that require confirmation and extension in the context of currently available chemotherapeutic options. Whether TOP2A amplification is an independent predictive marker of response to any type of treatment (chemotherapy or immune-based) has yet to be determined in the United States.
Media contact: Dako A/S Anne Thommesen, Corporate Communications, +45 40 63 95 93
Copyright Copyright Hugin ASA 2008. All rights reserved.
SOURCE: Dako Denmark A/S
Source: MARKET WIRE
Related Articles
- Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival
- ARIAD Announces Start of Phase 2 Clinical Trial of Oral Deforolimus in Patients With Metastatic, HER2-Positive Breast Cancer
- Kosan's Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
- Agendia's MammaPrint(R), the Only FDA-Cleared Breast Cancer Prognosis Test, is Now Widely Available to U.S. Patients
- Patients Welcome New Drug for Breast Cancer
- Kosan's Hsp90 Inhibitor, Tanespimycin, Shows Promising Antitumor Activity in Phase 2 Trial of Patients With HER2-Positive Metastatic Breast Cancer
- Agendia's MammaPrint(R) Breast Cancer Prognosis Test Validated By an Independent International Consortium
- Agendia's MammaPrint(R) Shows Significant Agreement With Other Multi-Gene Breast Cancer Prognosis Tests
- Interim Analysis of Phase III Trial Shows Avastin Plus Chemotherapy Improved Progression-Free Survival in Patients With First-Line Metastatic Breast Cancer
- Updated Results of Allos' Phase 3 Reach Study Confirm Survival Benefit in Patients With Brain Metastases From Breast Cancer
 |
 |
User Comments (0)
RSS Feeds